Samira Shaikhly Sells 2,178 Shares of Septerna (NASDAQ:SEPN) Stock

Septerna, Inc. (NASDAQ:SEPN) insider Samira Shaikhly sold 2,178 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $35.18, for a total transaction of $76,622.04. Following the completion of the transaction, the insider directly owned 793 shares in the company, valued at $27,897.74. This trade represents a 73.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Samira Shaikhly also recently made the following trade(s):

• On Friday, June 12th, Samira Shaikhly sold 6,250 shares of Septerna stock. The stock was sold at an average price of $35.08, for a total value of $219,250.00.
• On Monday, June 1st, Samira Shaikhly sold 5,935 shares of Septerna stock. The stock was sold at an average price of $28.93, for a total value of $171,699.55.
• On Tuesday, May 26th, Samira Shaikhly sold 11,798 shares of Septerna stock. The shares were sold at an average price of $30.06, for a total value of $354,647.88.

Septerna Stock Up 3.3%

Shares of SEPN opened at $34.61 on Thursday. Septerna, Inc. has a 52-week low of $10.48 and a 52-week high of $37.99. The stock has a fifty day simple moving average of $29.73 and a two-hundred day simple moving average of $27.55. The company has a market capitalization of $1.56 billion, a PE ratio of -42.73 and a beta of 2.28.

Septerna (NASDAQ:SEPN) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.23. Septerna had a negative net margin of 49.88% and a negative return on equity of 12.72%. The firm had revenue of $26.52 million during the quarter, compared to analyst estimates of $16.98 million. As a group, equities analysts anticipate that Septerna, Inc. will post -1.59 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on SEPN. Truist Financial raised their price target on shares of Septerna from $35.00 to $43.00 and gave the stock a “buy” rating in a report on Wednesday. Stifel Nicolaus assumed coverage on shares of Septerna in a research note on Friday, May 1st. They set a “buy” rating and a $43.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Septerna in a research report on Tuesday, April 21st. Cantor Fitzgerald restated an “overweight” rating and set a $60.00 price target on shares of Septerna in a research note on Tuesday, March 10th. Finally, Wall Street Zen lowered shares of Septerna from a “buy” rating to a “hold” rating in a research note on Saturday, March 14th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Septerna has an average rating of “Moderate Buy” and an average target price of $45.89.

Institutional Investors Weigh In On Septerna

A number of large investors have recently modified their holdings of the company. Avoro Capital Advisors LLC grew its stake in shares of Septerna by 8.1% during the third quarter. Avoro Capital Advisors LLC now owns 1,337,500 shares of the company’s stock worth $25,158,000 after purchasing an additional 100,000 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Septerna by 6.1% in the first quarter. Bank of New York Mellon Corp now owns 58,709 shares of the company’s stock valued at $1,411,000 after buying an additional 3,377 shares during the last quarter. Janus Henderson Group PLC acquired a new stake in Septerna in the first quarter valued at $21,334,000. Swiss National Bank purchased a new stake in Septerna during the 1st quarter worth about $531,000. Finally, First Light Asset Management LLC lifted its holdings in Septerna by 18.0% during the 1st quarter. First Light Asset Management LLC now owns 732,860 shares of the company’s stock worth $17,611,000 after buying an additional 112,049 shares during the last quarter.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.